Evidence map›Paper›PMID 33158257›Full record

ArticleMolecules (Basel, Switzerland)2020

Antihyperuricemic Effect of Urolithin A in Cultured Hepatocytes and Model Mice.

Shin-Ichi Adachi, Kazunori Sasaki, Shinji Kondo, Wataru Komatsu, Fumiaki Yoshizawa, Hiroko Isoda, Kazumi Yagasaki

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Shin-Ichi AdachiCenter for Bioscience Research and Education, Utsunomiya University, Utsunomiya 321-8505, Tochigi, Japan.
Kazunori SasakiAlliance for Research on the Mediterranean and North Africa (ARENA), University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8572, Ibaraki, Japan.
Shinji KondoCenter for Bioscience Research and Education, Utsunomiya University, Utsunomiya 321-8505, Tochigi, Japan.
Wataru KomatsuLaboratory of International Environmental Health, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan.
Fumiaki YoshizawaFaculty of Agriculture, Utsunomiya University, Utsunomiya 321-8505, Tochigi, Japan.ORCID 0000-0001-8799-7701
Hiroko IsodaAlliance for Research on the Mediterranean and North Africa (ARENA), University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8572, Ibaraki, Japan.
Kazumi YagasakiCenter for Bioscience Research and Education, Utsunomiya University, Utsunomiya 321-8505, Tochigi, Japan.ORCID 0000-0002-9494-9887
Utsunomiya University · JPUniversity of Tsukuba · JPDokkyo Medical University · JP

Funding

JSPS KAKENHI Grant Number JP15K07424JSPS KAKENHI Grant Number JP16K16273the Reginal Innovation Strategy Support Program Tochigi: 2014-2019
6 · The paper itself

Abstract

Hyperuricemia is defined as a disease with high uric acid (UA) levels in the blood and a strong risk factor for gout. Urolithin A (UroA) is a main microbial metabolite derived from ellagic acid (EA), which occurs in strawberries and pomegranates. In this study, we evaluated antihyperuricemic effect of UroA in both cultured hepatocytes and hyperuricemic model mice. In cultured hepatocytes, UroA significantly and dose-dependently reduced UA production. In model mice with purine bodies-induced hyperuricemia, oral administration of UroA significantly inhibited the increase in plasma UA levels and hepatic xanthine oxidase (XO) activity. In addition, DNA microarray results exhibited that UroA, as well as allopurinol, a strong XO inhibitor, induced downregulation of the expression of genes associated with hepatic purine metabolism. Thus, hypouricemic effect of UroA could be, at least partly, attributed to inhibition of purine metabolism and UA production by suppressing XO activity in the liver. These results indicate UroA possesses a potent antihyperuricemic effect and it could be a potential candidate for a molecule capable of preventing and improving hyperuricemia and gout.

Indexed as

HyperuricemiaAnimalsCell LineCoumarinsDisease Models, AnimalGout SuppressantsHepatocytesLiverMaleMiceMice, Inbred ICRUric Acid3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-oneCoumarinsGout SuppressantsUric AcidAML12 hepatocyteellagic acidhyperuricemiauric acidurolithin A

Identifiers

PMID33158257
PMCPMC7662530
OpenAlexW3097827106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.